Core Viewpoint - RespireRx Pharmaceuticals Inc. has received an order from the Securities and Exchange Commission (SEC) revoking the registration of its securities due to non-compliance with reporting requirements under the Securities Exchange Act of 1934 [2][4]. Summary by Sections The Order - On November 13, 2025, the SEC issued an order revoking the registration of RespireRx's securities effective November 14, 2025, due to the company's failure to file periodic reports since September 30, 2023 [2][4]. Findings - The SEC found that unsolicited quotations of RespireRx's common stock were submitted on the Expert Market of the OTC Link ATS, and the company had not complied with Exchange Act 13(a) and related rules [4]. Background - RespireRx submitted an offer of settlement on September 30, 2025, and awaited the SEC's decision during the government shutdown from October 1 to November 12, 2025. The settlement was accepted without any monetary fine, leading to the revocation of the registration of its common stock [5]. Future Plans - The company plans to register its common stock and possibly other classes on Form 10 after December 31, 2025, which will require filing two years of audited financial statements. The Form 10 will become effective 60 days after filing, and the company will need to remain current with required periodic filings thereafter [6]. About RespireRx Group - RespireRx Pharmaceuticals Inc. and its subsidiaries focus on developing treatments for psychiatric and neurological disorders, including epilepsy, ADHD, and obstructive sleep apnea. The company is working on a pipeline of new and repurposed drug products based on its patent portfolios [8][9]. EndeavourRx LLC: Neuromodulators - EndeavourRx has developed a family of AMPAkines, including CX717 and CX1739, which have shown promise in treating CNS-driven disorders and have completed Phase 1 and Phase 2 clinical trials [10][11]. GABAkines - The company has in-licensed GABAkines for treating epilepsy and pain, with KRM-II-81 demonstrating significant anti-convulsant and analgesic activity in preclinical studies [13][14][15]. ResolutionRx Ltd: Pharmaceutical Cannabinoids - ResolutionRx is developing a new formulation of dronabinol for obstructive sleep apnea, with a total budget of approximately $16.5 million for the program. Dronabinol has shown significant improvement in OSA symptoms in previous trials [17][18].